Business Update Continued progress on XF-73 partnering discussions Susan Koppy appointed to drive business development activities $2bn XF-73 Nasal market opportunity Brighton, United Kingdom - 29th June 2.
Destiny Pharma PLC (AIM:DEST, OTC:DTTYF), the Brighton-based biotechnology firm, has progressed with partnership talks around XF-73 Nasal, its flagship.
Destiny Pharma progress lauded by broker proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
(2)
Vancouver, British Columbia (Newsfile Corp. - April 29, 2021) - iCo Therapeutics ( iCo or the Company ) (TSXV: ICO) (OTC: ICOTF) today reported financial results for the year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ( IFRS ).
William Jarosz, CEO of iCo Therapeutics Inc., noted We were very pleased by the progress of our Oral Amp B program during the year with our compound being safe and well tolerated in Phase 1b clinical trials and potential as a therapeutic agent for novel Coronavirus. We are also excited for the new strategic directions that are open for us in this new year with Satellos, and the associated concurrent financing, previously announced.